The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2015
Filed:
Jul. 09, 2014
Applicant:
N30 Pharmaceuticals, Inc., Boulder, CO (US);
Inventors:
Assignee:
Nivalis Therapeutics, Inc., Boulder, CO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 215/04 (2006.01); A61K 31/44 (2006.01); C07D 417/10 (2006.01); C07D 215/20 (2006.01); C07D 217/16 (2006.01); C07D 239/34 (2006.01); C07D 241/42 (2006.01); C07D 253/10 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 403/10 (2006.01); C07D 405/04 (2006.01); C07D 409/04 (2006.01); C07D 413/10 (2006.01); C07C 65/105 (2006.01); C07C 65/24 (2006.01); C07D 213/79 (2006.01); C07D 239/28 (2006.01); C07D 241/24 (2006.01); C07D 295/155 (2006.01); C07D 215/06 (2006.01); C07D 239/74 (2006.01); C07D 409/14 (2006.01); C07D 215/60 (2006.01); C07D 239/26 (2006.01);
U.S. Cl.
CPC ...
C07D 417/10 (2013.01); C07D 215/20 (2013.01); C07D 217/16 (2013.01); C07D 239/34 (2013.01); C07D 241/42 (2013.01); C07D 253/10 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 403/10 (2013.01); C07D 405/04 (2013.01); C07D 409/04 (2013.01); C07D 413/10 (2013.01); C07C 65/105 (2013.01); C07C 65/24 (2013.01); C07D 213/79 (2013.01); C07D 239/28 (2013.01); C07D 241/24 (2013.01); C07D 295/155 (2013.01); C07D 215/06 (2013.01); C07D 239/74 (2013.01); C07D 409/14 (2013.01); C07D 215/60 (2013.01); C07D 239/26 (2013.01);
Abstract
The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.